Trial Profile

Phase Ib Trial of Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients: BladderGATE Study

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 23 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; BCG
Indications Bladder cancer
Focus Adverse reactions; Therapeutic Use
Acronyms BladderGATE

Most Recent Events

20 May 2024 Planned End Date changed from 1 Feb 2024 to 1 Sep 2024.
20 May 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Jun 2024.
27 Jan 2024 Results of safety and efficacy, presented at the 2024 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com